Comparing Decoy Therapeutics (DCOY) and The Competition

Decoy Therapeutics (NASDAQ:DCOY) is one of 456 publicly-traded companies in the “Pharmaceutical Preparations” industry, but how does it compare to its competitors? We will compare Decoy Therapeutics to similar businesses based on the strength of its analyst recommendations, dividends, risk, institutional ownership, earnings, profitability and valuation.

Analyst Recommendations

This is a breakdown of current ratings for Decoy Therapeutics and its competitors, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Decoy Therapeutics	1	0	1	0	2.00
Decoy Therapeutics Competitors	4894	9963	15988	376	2.38

Decoy Therapeutics currently has a consensus price target of $2.50, indicating a potential upside of 238.39%. As a group, “Pharmaceutical Preparations” companies have a potential upside of 63.62%. Given Decoy Therapeutics’ higher possible upside, analysts clearly believe Decoy Therapeutics is more favorable than its competitors.

Valuation and Earnings

This table compares Decoy Therapeutics and its competitors gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Decoy Therapeutics	N/A	-$5.58 million	-0.02
Decoy Therapeutics Competitors	$432.12 million	-$67.78 million	-10.65

Decoy Therapeutics’ competitors have higher revenue, but lower earnings than Decoy Therapeutics. Decoy Therapeutics is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Decoy Therapeutics has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Decoy Therapeutics’ competitors have a beta of 5.48, suggesting that their average share price is 448% more volatile than the S&P 500.

Insider and Institutional Ownership

11.9% of Decoy Therapeutics shares are held by institutional investors. Comparatively, 39.1% of shares of all “Pharmaceutical Preparations” companies are held by institutional investors. 0.3% of Decoy Therapeutics shares are held by insiders. Comparatively, 13.9% of shares of all “Pharmaceutical Preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Decoy Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Decoy Therapeutics	N/A	-401.05%	-155.77%
Decoy Therapeutics Competitors	-2,662.14%	-363.93%	-42.95%

Summary

Decoy Therapeutics competitors beat Decoy Therapeutics on 9 of the 13 factors compared.

Decoy Therapeutics Company Profile

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.